Harris County IVF Clinics Report 6-Point Higher Live Birth Rates Than Chicago. The Reason Has Nothing to Do With Quality.
The Number Everyone Looks At First Is the One That Misleads the Most
Pull up the CDC's ART Fertility Clinic Success Rates report and sort by live birth rate per egg retrieval. The pattern that emerges is counterintuitive enough that most patients assume it reflects quality: clinics in Texas, a state with no IVF insurance mandate where patients pay $15,000 to $22,000 per cycle out of pocket, consistently outperform clinics in Illinois, a state that has mandated IVF coverage since 1991. Harris County clinics in Houston average roughly 5 to 8 percentage points higher live birth rates than comparable clinics in Cook County. That looks like a quality gap. It is not. It is a measurement artifact produced by who can afford to walk through the door.
That distinction is not semantic. If you are a patient comparing clinics across county lines, or deciding whether to stay in your insurance network or travel to a clinic with a more impressive published rate, the raw number is not just unhelpful. It is actively pointing you in the wrong direction. The counties with the best published IVF outcomes are, almost by construction, the counties where financial barriers have already removed the patients least likely to succeed.
How the CDC Reports Success Rates, and What the Denominator Hides
The CDC's annual ART Surveillance report tracks outcomes at every fertility clinic in the country. The primary metric most patients reference is live birth rate per intended egg retrieval: the share of stimulation cycles that ultimately produce a baby. In 2021, the national average across all age groups was approximately 33 percent. The report publishes this figure by clinic, by age band, and by broad diagnosis category, and the data is detailed enough that a motivated patient can compare two specific clinics in different cities.
What the report cannot do is control for patient prognosis within any of those categories. A clinic serving predominantly 30-year-old patients with regular cycles and strong ovarian reserve will post different numbers than a clinic serving 42-year-old patients with diminished ovarian reserve, even if both deliver technically identical care. Age-stratified data helps at the margins, but it does not capture the full distribution of ovarian reserve, male factor severity, prior failure history, or the other biomarkers that actually predict outcomes. Within the 38-to-40 age band, a patient with an AMH of 2.1 ng/mL and 14 antral follicles has roughly double the probability of success compared to a patient with an AMH of 0.4 ng/mL and 3 antral follicles. The CDC groups both patients together.
The Society for Assisted Reproductive Technology publishes more granular patient predictor data, and research has demonstrated that case-mix adjustment can shift a clinic's perceived performance ranking by as much as 40 percentile points. A clinic ranked in the 60th percentile on raw live birth rates might belong in the 80th percentile after adjustment for patient severity. The gap runs in both directions, and the clinics most likely to be underranked are those that treat the hardest cases, which are overwhelmingly concentrated in mandate states.
The Mandate Effect: What Cook County Reveals About Patient Selection
Illinois passed a comprehensive IVF insurance mandate in 1991. Today, most employer-sponsored health plans in the state must cover IVF, including egg retrievals and embryo transfers. The practical result is that Cook County has one of the highest IVF utilization rates in the country. Research published in Fertility and Sterility has consistently shown that mandate states achieve 2 to 4 times higher utilization rates per 1,000 women of reproductive age compared to states without coverage requirements.
Higher utilization means a broader patient population. When cost is not a barrier, the pool of patients seeking IVF expands to include women who would otherwise self-select out entirely: older patients who cannot justify an $18,000 financial risk on uncertain odds; patients with known poor-prognosis diagnoses like premature ovarian insufficiency or severe male factor who want to attempt treatment regardless of published probabilities; couples pursuing a third or fourth cycle after prior failures. All of those patients belong in the treatment pool. That is precisely what insurance access is supposed to accomplish.
But it also means Cook County clinics are working with a fundamentally different patient mix than Harris County clinics. In Houston, the $15,000 to $22,000 out-of-pocket cost functions as a powerful filter before a patient ever schedules a consultation. The patients who do proceed in non-mandate counties tend to skew younger, present with better biomarkers on initial workup, and have often waited until their clinical profile suggests favorable odds. The AMH levels, antral follicle counts, and semen analyses that prompt a Texas patient to move forward through egg retrieval are, on average, more favorable than those of the broader Cook County population that insurance access draws in.
The Age Distribution Pattern
This becomes quantifiable when you look at the age distribution of IVF patients by state. Population-level utilization data compiled by RESOLVE: The National Infertility Association shows a consistent pattern: in mandate states, a larger share of IVF cycles are performed on women over 40. In non-mandate states, a larger share are performed on women under 35. This is not because older women in Harris County do not want children. It is because they are calculating the cost against the odds, and many are deciding not to proceed. The patients who remain in the non-mandate pool are, on average, better bets. The published success rate reflects that bet, not the clinic's technical capability.
What Egg Retrieval Volume Reveals That Success Rates Do Not
There is a second metric buried in the CDC data that most patients never examine: the number of eggs retrieved per stimulation cycle. This matters because IVF is increasingly practiced as a cumulative strategy rather than a single-attempt procedure. One egg retrieval might yield 10 mature oocytes, of which 7 fertilize normally, of which 4 develop to blastocyst stage, of which 2 pass preimplantation genetic testing (PGT-A), of which 1 results in a live birth on first transfer. The per-transfer success rate at the end of that chain looks reasonable. The per-retrieval efficiency, meaning how many usable embryos were produced from a single surgical procedure, is the upstream variable that determines how many total retrievals a patient will ultimately need.
County-level data on mean eggs retrieved per cycle exposes another layer of the selection effect. In Cook County and Middlesex County (the greater Boston area, where Massachusetts has had a mandate since 1987), mean egg yield per retrieval tends to be lower than in selective non-mandate practices. Again: this reflects the patient mix, not laboratory quality. A patient with 3 antral follicles is expected to produce fewer eggs than a patient with 15, regardless of which clinic performs the retrieval or how skilled the embryologist is.
But in Middlesex County specifically, laboratory protocols and embryology staff experience are exceptional. High-volume programs in that county post blastocyst development rates from two-pronuclear embryos that consistently rank among the highest in published literature. The efficiency gap from a broader patient pool is partially offset by superior downstream lab performance. This distinction matters because fertilization rates, blastocyst development rates, and post-thaw embryo survival rates are substantially harder to inflate through patient selection than per-cycle live birth rates. They measure what happens after the eggs are in the dish, not which patients were financially able to reach the dish in the first place. In Harris County, several high-volume clinics post strong blastocyst development rates as well. But because the patient pool skews toward better-prognosis cases, it becomes nearly impossible to isolate the contribution of lab quality from the contribution of patient selection using published numbers alone.
What the Coming Mandate Expansion Will Do to Published Data
As of 2024, 21 states have passed some form of IVF insurance coverage mandate, up from 16 states in 2020. Several high-population non-mandate states are actively debating coverage legislation. Florida (Miami-Dade County, Orange County), Georgia (Fulton County), and North Carolina (Wake County) have active legislative conversations around fertility coverage. California's AB 2088 extended mandate requirements to larger employer plans beginning in 2025, which will affect clinic data in Los Angeles County and San Francisco County starting in the next CDC reporting cycle.
When these mandates pass, the near-term effect on published clinic success rates will be a measurable decline. Not because quality drops. Because the patient pool broadens. Any analyst watching Florida clinic data over the next three years should expect live birth rates to fall 2 to 5 percentage points across Miami-Dade and Orange County clinics as coverage access expands, and should interpret that decline as evidence the mandate is functioning as intended, not as evidence that Florida clinics deteriorated.
This is a predictable, replicable pattern. Massachusetts clinics in Middlesex County saw a comparable dip in the mid-1990s after full mandate implementation. Illinois saw it in the early 2000s as enforcement tightened. The clinics did not get worse. The patient population got broader, and the published number stopped reflecting a filtered sample. For patients comparing a Miami clinic operating before mandate implementation to a counterpart in a market that has already absorbed mandate-driven utilization growth, the raw CDC numbers will show the Miami clinic outperforming. That comparison is almost entirely an artifact of timing and access policy, not clinical capability.
What This Actually Means When You Are Making a Decision Today
The raw published success rate should carry very little weight in a cross-county clinic comparison. The far more useful approach is to ask any clinic you are evaluating three specific questions before relying on any outcome data they present.
Ask for the clinic's live birth rate for patients who match your specific clinical profile: your AMH level, your antral follicle count, your diagnosis. Not the overall rate. Not the age-band average. Most reputable clinics have this data internally and will share it if asked. If they will not, that tells you something about how they are managing expectations.
Ask for the clinic's blastocyst development rate from two-pronuclear embryos. This metric is less correlated with patient selection effects and more reflective of what the embryology laboratory actually does well. A clinic consistently achieving 60 to 65 percent blastocyst development is operating a high-performing lab. A clinic below 45 percent warrants closer scrutiny before you commit to a retrieval cycle there.
Ask about the clinic's policy on cycle cancellation for poor responders. Clinics willing to cancel a low-response cycle rather than proceed to retrieval at poor odds are demonstrating clinical judgment that protects patients from wasted procedures and expense. In non-mandate counties where each cycle represents a significant financial commitment, this policy is a more reliable signal of clinical integrity than any success rate on a website.
The insurance mandate environment in your county also shapes what you should expect from a consultation. In Cook County or Middlesex County, the financial pressure to proceed at all costs is structurally lower, which tends to produce more conservative clinical recommendations. In Harris County or Maricopa County (Phoenix), where patients are paying out of pocket, there is an implicit asymmetry between a clinic's incentive to proceed and a patient's interest in being counseled to wait.
None of this means exceptional IVF care is unavailable in non-mandate counties. Some of the most technically skilled embryologists in the country practice in Houston, Phoenix, and Dallas. The point is that the number on the clinic's website, or in the CDC report, was never designed to answer the question you are asking when you type "best IVF clinic near me."
For a comparison that accounts for mandate status, cost per retrieval cycle, and patient mix context across Harris County, Cook County, and more than 200 other counties, explore the data at Feralyx. The most expensive mistake in IVF is not choosing the wrong stimulation protocol. It is choosing the wrong clinic because a statistic that measures who was in the room, not what happened in the lab, pointed you there.
Related Analysis
Other Smart Technology Investments tools that bear on this decision: